This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Luteal Phase Commencing of Growth Hormone

This study has been completed.
Ren-Tıp ART Center, Bursa, Turkey
Information provided by:
Gulhane School of Medicine Identifier:
First received: November 19, 2007
Last updated: November 20, 2007
Last verified: November 2007
Commencing of growth hormone in luteal phase when follicular cohort for the next cycle is being gathered may increase mature oocytes in poor responder

Condition Intervention Phase
Infertility Drug: Norditropin pen Phase 4

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Growth Hormone co-Treatment Within a GnRH Agonist Long Protocol in Patients With Poor Ovarian Response

Resource links provided by NLM:

Further study details as provided by Gulhane School of Medicine:

Primary Outcome Measures:
  • mature oocyte number [ Time Frame: 2 years ]

Secondary Outcome Measures:
  • pregnancy rate [ Time Frame: 2 years ]

Enrollment: 61
Study Start Date: January 2005
Study Completion Date: November 2007
Groups/Cohorts Assigned Interventions
poor responder
Drug: Norditropin pen
12 IU per day


Ages Eligible for Study:   20 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
poor response to previous COH in the same center

Inclusion Criteria:

  • Poor responder

Exclusion Criteria:

  • FSH >20 IU
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00561769

Ren Tıp ART Center
Bursa, Turkey, 16200
Sponsors and Collaborators
Gulhane School of Medicine
Ren-Tıp ART Center, Bursa, Turkey
Study Director: Tansu Kucuk, Assoc Prof GATA Ankara
  More Information Identifier: NCT00561769     History of Changes
Other Study ID Numbers: GATA 2005-21
Study First Received: November 19, 2007
Last Updated: November 20, 2007

Keywords provided by Gulhane School of Medicine:
poor responder
growth hormone

Additional relevant MeSH terms:
Genital Diseases, Male
Genital Diseases, Female
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs processed this record on August 18, 2017